Thomas Moriarty - 15 Dec 2022 Form 4 Insider Report for CVS HEALTH Corp (CVS)

Role
EVP & General Counsel
Signature
/s/ Thomas M. Moriarty
Issuer symbol
CVS
Transactions as of
15 Dec 2022
Transactions value $
-$3,369,960
Form type
4
Filing time
16 Dec 2022, 15:14:45 UTC
Previous filing
30 Jun 2022
Next filing
04 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CVS Common Stock Options Exercise $7.88M +101K +16.6% $78.05 709K 15 Dec 2022 Direct
transaction CVS Common Stock Sale -$9.94M -101K -14.24% $98.40 608K 15 Dec 2022 Direct F1
transaction CVS Common Stock Options Exercise $2.27M +36.5K +6% $62.21 645K 15 Dec 2022 Direct
transaction CVS Common Stock Sale -$3.58M -36.5K -5.66% $98.24 608K 15 Dec 2022 Direct F2
holding CVS Common Stock 159K 15 Dec 2022 By GRAT
holding CVS Stock Unit 47.3K 15 Dec 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CVS Stock Option Options Exercise $0 -101K -80.64% $0.00 24.2K 15 Dec 2022 Common Stock 101K $78.05 Direct F3
transaction CVS Stock Option Options Exercise $0 -36.5K -100% $0.00* 0 15 Dec 2022 Common Stock 36.5K $62.21 Direct F4
holding CVS Stock Option 71.7K 15 Dec 2022 Common Stock 71.7K $104.82 Direct F5
holding CVS Stock Option 50.5K 15 Dec 2022 Common Stock 50.5K $54.19 Direct F6
holding CVS Stock Option 98.6K 15 Dec 2022 Common Stock 98.6K $58.34 Direct F7, F8
holding CVS Stock Option 117K 15 Dec 2022 Common Stock 117K $74.30 Direct F9
holding CVS Stock Option 46.8K 15 Dec 2022 Common Stock 46.8K $101.09 Direct F10
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 All sales were effected pursuant to a Rule 10b5-1 plan.
F2 All sales were effected pursuant to a Rule 10b5-1 plan.
F3 Option became exercisable in four equal annual installments, commencing 4/3/2018.
F4 Option became exercisable in four equal annual installments, commencing 4/1/2019.
F5 Option became exercisable in four equal annual installments, commencing 4/1/2017.
F6 Option became exercisable in four equal annual installments, commencing 4/1/2020.
F7 The number of shares subject to the option were calculated using a 30-day average price.
F8 Option became exercisable in four equal annual installments, commencing 4/1/2021.
F9 Option became exercisable in four equal annual installments, commencing 4/1/2022.
F10 Option becomes exercisable in four equal annual installments, commencing 4/1/2023.